^
Association details:
| Biomarker: | CDKN2A mutation + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Published date:
10/08/2021
Excerpt:
These findings held in patients with high TMB (median OS, LOF vs. WT 10.5 vs. 22.3 months; p = 0.069) and PD-L1 ≥ 50% (median OS, LOF vs. WT 11.1 vs. 24.2 months; p = 0.020), as well as in an independent dataset….CDKN2A LOF negatively impacts clinical outcomes in advanced NSCLC treated with ICB, even in high PD-L1 and high TMB tumors.
DOI:
https://doi.org/10.1038/s41598-021-99524-1
